% | $
Quotes you view appear here for quick access.

Galena Biopharma, Inc. Message Board

  • mmazza333 mmazza333 Aug 9, 2013 5:16 PM Flag

    10 Million to acquire US rights to Abstal

    The decrease of approximately $11.9 million in our cash and cash equivalents from December 31, 2012 to June 30, 2013 was attributable primarily to cash used in operations, with our initial payment of approximately $10.0 million to acquire U.S. commercialization rights to Abstral, offset by cash from financing activities related to our Loan financing on May 8, 2013 described in Note 6 of the Notes to the Condensed Consolidated Financial Statements.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.4661+0.1161(+33.17%)Jun 30 4:00 PMEDT